April 1, 2026, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the launch of two new exam prep bundles for its Certified Advanced Biotherapies Professional (CABP) credentialing program: the CABP Exam Prep Complete Bundle and the CABP Exam Prep Core Bundle. The new bundles are designed to help candidates prepare for AABB’s CABP exam. [Read more…]
What Stem Cell Clinics Do You Trust?
On a global basis, stem cell clinics have proliferated in recent years. This article explores leading stem cell centers within the U.S. and worldwide. Read on to learn about this emerging area of medicine. [Read more…]
Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing
Giessen, Germany – 17.03.2026 – Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is introducing the platform to the market ahead of its planned commercial launch later this year.
Archimedes® One was developed to address a central challenge in cell therapy manufacturing: how to scale adherent cell processes without compromising biology or introducing unnecessary complexity. [Read more…]
Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 17, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the safety of allogeneic mesenchymal stem cell therapies across a broad range of human clinical indications.
The study, titled “Safety of Allogeneic Mesenchymal Stromal Cell Therapy Across Human Clinical Indications: A Systematic Review of Landmark Clinical Trials and Published Safety Evidence,” reviewed more than 15 years of published human clinical research across more than 60 stem cell studies, approximately 4,000 patients, and multiple disease categories, including cardiovascular, pulmonary, autoimmune, gastrointestinal, renal, and orthopedic conditions. [Read more…]
Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease
March 11, 2026, Lexington, MA / United States — Cytonome-ST today congratulated Sumitomo Pharma Co., Ltd. following the company’s announced receipt of regulatory approval for the world’s first iPS cell-derived regenerative medicine for the treatment of Parkinson’s disease.
https://www.sumitomo-pharma.com/news/20260306.html [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 18
- Next Page »